Trial Profile
A non-randomized, open-label, single-dose, crossover study to evaluate the dose proportionality of the final fixed dose combination formulation of Coreg CR [carvedilol] and lisinopril.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Carvedilol/lisinopril (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 12 Nov 2007 New trial record.